Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Uveal Melanoma 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of the Lung 1Skin Neoplasms 1Osteosarcoma 1Melanoma 1Breast Neoplasms 1

Interventions

aldesleukin 15Cyclophosphamide 15fludarabine phosphate 12fludarabine 11Interleukin-2 10Nivolumab 6Ipilimumab 6Temozolomide 5pembrolizumab 3Fluorouracil 3trametinib 2sonidegib 2dabrafenib 2binimetinib 2Whole-Body Irradiation 2Vemurafenib 2Tacrolimus 2Sodium Chloride 2Sirolimus 2Radiotherapy 2Radiation 2Peptides 2HhAntag691 2Gefitinib 2Dacarbazine 2Cyclosporine 2Cetuximab 2Capecitabine 2veliparib 1varlilumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Skin Neoplasms × glembatumumab vedotin × Clear all
NCT02302339 2019-09-06

A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

Celldex Therapeutics

Phase 2 Terminated
132 enrolled 16 charts
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡